Additionally, aberrant expression of lymphoid antigens, including CD56 (41%, 7/17), CD7 (37%, 7/19), CD22 (15%, 2/13), CD19 (11%, 2/19) and cCD79a (7%, 1/15), was observed in some AML cases. This evidence concerns the gene CD22 and acute myeloid leukemia.